Related Experiment Video
Updated: May 23, 2026

Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
Biomarkers in community-acquired pneumonia
1Medical Clinic I, University Clinic RWTH Aachen, Germany.
Abstract:
A relevant problem in the management of pulmonary infections is the low specificity of clinical symptoms for the exact diagnosis and the need of antibiotic therapy. An ideal biomarker for bacterial pulmonary infections should allow a rapid diagnosis, have a prognostic value and facilitate therapeutic decision making. The two biomarkers currently needed in clinical use are C-reactive protein and procalcitonin. C-reactive protein is very unspecific and elevated in bacterial as well as viral infections. Today, procalcitonin is the best validated biomarker for pulmonary infections. In several interventional studies procalcitonin-guided therapy has proven to allow a significant reduction of duration and frequency of antibiotic therapy. However, for the evaluation of prognosis in community-acquired pneumonia, new cardiovascular biomarkers are superior compared with inflammatory markers, especially for the determination of long-term mortality. The combination of several biomarkers reflecting different pathophysiological pathways has the potential to improve the management of community-acquired pneumonia in the future.
Related Concept Videos
Pneumonia III: Complications and Assessment
Atypical Pneumonia
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...